CHR Awarded New Patent on Using FMR1 Gene to Screen Egg Donors

voice_1511_patentThis article is a part of the November 2015 issue of CHR VOICE, our monthly newsletter.

In October 2015, CHR was awarded another patent by the U.S. Patent and Trademark Office (USPTO). The patent describes an improved method of selecting egg donors with normal ovarian reserve who can be expected to produce a good number of eggs in an egg donation cycle. CHR’s research over the last 5-6 years have focused on the role of the FMR1 gene—particularly the genotypes and sub-genotypes defined by the number of CGG repeat counts on the gene —in the regulation of ovarian reserve over the long term. Based on this research published in various medical journals, CHR was able to refine our egg donor screening and ensure optimum pregnancy chances for the recipients of donated eggs.

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned reproductive endocrinologist, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.